Emvision Medical Devices Ltd (EMV)
Australian Securities Exchange · Australia · prices in AUD · close of 23 Oct 2026
Key indicators
| Last close | AUD 1.460 |
|---|---|
| 52-week range | 1.455 – 1.955 |
| Return, 1 month / 3 months | −16.1% / −10.2% |
| Return, 1 year / 3 years | −21.5% / −0.7% |
| Trend | Below its 200-day average |
| RSI (14) | 34 |
| Volatility (1 year) | 41.2% |
| Worst drawdown (1 year) | -25.3% |
| Average daily value traded | 0.06M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Emvision Medical Devices is an Australian medical technology company based in Sydney that develops portable brain imaging devices. Its main product is a compact scanner that uses electromagnetic waves to image the brain, intended to help clinicians assess suspected stroke and other neurological conditions outside traditional hospital imaging suites. The company works with hospitals, emergency services and research partners to develop and test its devices, aiming to bring brain imaging to ambulances, clinics and bedside settings.
Emvision Medical Devices Ltd trades under the code EMV on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Emvision Medical Devices Ltd (EMV) trades on the Australian Securities Exchange in Australia. It last closed at AUD 1.460 on 23 October 2026.
Its price-based Market X-Ray is 65 out of 100 (a fair price profile), ranking 534 of 1,816 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 21.5% and over the last three months it fell 10.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 67 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -13.1% | ||
| From 52-week high | -25.3% | ||
| Momentum | 51 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -10.2% | ||
| 6-month return | -19.6% | ||
| 12-month return, skipping the last month | -6.5% | ||
| Stability (higher is calmer) | 83 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 41.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.3% | ||
| Liquidity | 56 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.06M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −9.3% |
|---|---|
| 1 month | −16.1% |
| 3 months | −10.2% |
| 6 months | −19.6% |
| 1 year | −21.5% |
| 3 years | −0.7% |
| 5 years | −50.2% |
Signals
| 50-day / 200-day average | 1.692 / 1.681 |
|---|---|
| Golden / death cross (60 days) | Golden, 21 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.067 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.